Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EPS (Weighted Average and Diluted) (2016 - 2023)

Ekso Bionics Holdings (EKSO) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.33 as the latest value for Q1 2023.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 8.33% to -$0.33 in Q1 2023 year-over-year; TTM through Mar 2023 was -$1.13, a 25.56% decrease, with the full-year FY2022 number at -$1.16, down 31.82% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.33 for Q1 2023 at Ekso Bionics Holdings, down from -$0.24 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.04 in Q3 2019 to a low of -$1.88 in Q2 2020.
  • A 5-year average of -$0.36 and a median of -$0.26 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 138.92% in 2019, then crashed 1600.0% in 2021.
  • Ekso Bionics Holdings' EPS (Weighted Average and Diluted) stood at $0.04 in 2019, then crashed by 1154.93% to -$0.42 in 2020, then soared by 38.38% to -$0.26 in 2021, then increased by 7.69% to -$0.24 in 2022, then tumbled by 37.5% to -$0.33 in 2023.
  • Per Business Quant, the three most recent readings for EKSO's EPS (Weighted Average and Diluted) are -$0.33 (Q1 2023), -$0.24 (Q4 2022), and -$0.33 (Q3 2022).